Brian D. Lehmann, Ph.D.

Brian D. Lehmann is a Research Assistant Professor of Medicine at the Vanderbilt School of Medicine. After graduating from the University of Illinois, Lehmann earned a Ph.D. in Anatomy and Cell Biology at East Carolina University in 2007. He continued his postgraduate training at Vanderbilt University. His research expertise lies at the intersection of cancer biology and bioinformatics. His unique understanding of both has led to the successful characterization of distinct molecular subgroups for triple-negative breast cancer (TNBC). These distinct transcriptional subtypes of TNBC display unique biology and differential sensitivity to conventional and targeted therapy. These findings have made a substantial impact within the field and subsequent studies have led to several multi-institutional clinical trials aligning TNBC patients with targeted therapy. He has authored or co-authored over 50 articles published in the peer-reviewed scientific literature. These include novel characterization of targetable gene fusions in TNBC and melanoma, clinical evaluation of androgen receptor antagonist (AR) and PI3K inhibition in AR+ TNBC and development of novel tools for next generation sequencing analysis.   He is currently exploring mechanisms of immune suppression in TNBC.